Edition:
United States

Analyst Research

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Sadif Analytics Prime
$25.00
Provider : Wright Reports
$75.00
Provider : Directors Deals Ltd.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Actavis plc confirms generic neupro patent challenge


Friday, 22 Aug 2014 04:05pm EDT 

Actavis plc:Confirms that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr.Actavis' ANDA product is a generic version of UCB's Neupro, which is indicated for the treatment of signs and symptoms of idiopathic Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome (RLS). 

Latest Developments forAfroCentric Investment Corporation Ltd

Company Quote

515.0
-5.0 -0.96%
22 Jul 2016